

# High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review

Jude O. Okoye

Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, College of Medicine, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria

## Access this article online

Website: [www.avicennajmed.com](http://www.avicennajmed.com)

DOI: 10.4103/ajm.ajm\_19\_20

## Quick Response Code:



## ABSTRACT

Globally, prostate cancer (PCa) is the second most preponderant cancer in men. It contributes to the high mortality-to-incidence ratio reported in West Africa and Asia largely due to low screening. The mortality risk is determined or predicted based on the prevalence of high-risk or aggressive PCa using a scoring or grading system such as Gleason score (GS), Gleason grade (GG), and prostate-specific antigen (PSA) level. In this review, peer-reviewed articles found on databases such as Google Scholar, Scopus, Web of Science, PubMed Central and, EMBASE were selected based on adherence to clinical guidelines for the classification of PCa. In West Africa and Asia, the result revealed that the frequency of high-risk PCa was 42% and 51.2% based on GS, 48.8% and 25.3% based on GG pattern, and 87.5% and 44.3% based on PSA level >10 ng/mL, respectively. Data revealed a high prevalence of high-risk PCa both in West Africa and Asia when compared with developed countries. However, the prevalence of high-risk PCa is higher in West Africa than in Asia. Studies have shown that high-risk PCas are associated with germline mutations and such mutations are prevalent in blacks and Asians than in whites. Thus, testing for germline mutations in patients with GS of  $\geq 7$ , GG  $\geq 3$ , high prostate density, low prostate volume, and PSA levels of >4.0 ng/mL may identify those at risk of developing lethal PCa and could reduce the mortality rates in Asia and West Africa.

**Key words:** Gleason grade, Gleason system, mortality risk, prostate cancer, PSA level

## INTRODUCTION

Benign prostate hyperplasia (BPH) accounts for 78.3% of all prostate-related diagnoses and increases from 20% to 90% in men who are 40–80 years of age, whereas prostatic adenocarcinoma accounts for 92.4%–96.7% of all malignant tumors in the prostate.<sup>[1-3]</sup> Globally, the odds of developing prostate cancer (PCa) are 1 in 18 and the odds range from 1 in 52 for low sociodemographic index (SDI) countries to 1 in 9 in high SDI countries.<sup>[4]</sup> However, the mortality rate per new cases appears to be higher in the former than the latter. The reason for this could be linked to poverty, family history, genetics, and race.<sup>[5]</sup> This review evaluated and compared the aggressiveness of PCa in West Africa and Asia against that of developed countries, using diagnostic

tools such as Gleason score (GS), Gleason grade (GG), and prostate-specific antigen (PSA) level.

## MATERIALS AND METHODS

Peer-reviewed articles published between the year 2000 and 2020 were selected and screened using the PRISMA standard [Figure 1]. Sources of articles include Google Scholar, Scopus, Web of Science, PubMed Central, and EMBASE. Full-texts on clinical risk stratification of PCa cases were selected based on authors' adherence to the recommendations and reports

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**Cite this article as:** Okoye JO. High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review. *Avicenna J Med* 2020;10:93-101.

**Address for correspondence:** Mr. Jude Ogechukwu Okoye, Ph.D in view, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, College of Medicine, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria.  
E-mail: [jog.okoye@unizik.edu.ng](mailto:jog.okoye@unizik.edu.ng)

of the National Comprehensive Cancer Network (NCCN), and International Society of Urological Pathology.<sup>[6,7]</sup> To determine mortality risk or prevalence of aggressive PCa among Asian and West African patients in literature, PCa was clinically classified into low-, intermediate-, and high-risk groups using grading or scoring systems such as Gleason score (GS:  $\leq 6$ , 7, and  $\geq 8$ ), Gleason grade (GG: 1 through 5) and PSA level ( $< 4$ , 4–10, and  $> 10$  ng/mL). All cases with unknown or unassigned GS, GG, or PSA level were excluded. Chi-square analysis (GraphPad Prism version 6) was used to compare the frequency of high-risk PCa between West Africa and Asia.

## MORTALITY-TO-INCIDENCE RATIOS AND SCREENING FOR PROSTATE CANCER

Over 1 million men are diagnosed with PCa every year with approximately 28% mortality.<sup>[8]</sup> Data from the GLOBOCAN 2012 report, as reviewed by Chen *et al.*,<sup>[9]</sup> show a significant inverse relationship between mortality-to-incidence ratios (MIRs) and life expectancy ( $P = 0.0002$ ), with Nigeria having the second-lowest life expectancy (55 years) and the

highest MIR (80.6) in the world. According to the report, the MIR (pooled) is also higher in Asian countries (51.6) than in the USA (13.0), Germany (18.4), and UK (23.3). The lower pooled MIR (18.2) and high life expectancy (80.3 years) in developed countries (the USA, Germany, and UK) when compared with that of Africa and Asia may be linked to low poverty status, high health budget, awareness and high screening services in developed countries. This is further underscored by the fact that a higher incidence rate of PCa is seen in the UK's affluent regions, whereas a higher mortality rate is observed in the UK's deprived regions.<sup>[10]</sup> Lower incidence of PCa is reported in China (9.1) than in the USA (75.7); however, higher mortality rate per new cases is reported in China than in the USA.<sup>[11-15]</sup> The latter could be ascribed to higher prevalence aggressive PCa in China (30%) than in the USA (0.5%).<sup>[13-15]</sup> Despite China's advanced economy, it accounts for 34% of the total PCa-related mortality in Asia.<sup>[16]</sup> This suggests that there are other co-founding factors to high mortality rate in Asia apart from poverty. To detect PCa early, some biomarkers have been proposed. One such biomarker is the PSA.





Figure 1: PRISMA flow diagram on prevalence of PCa/BPH and its risk stratification

Considering the sensitivity (81.9%–89.5%) and specificity (38.2%–52.3%) of PSA (at >4 ng/mL), many countries including Asian countries have been scaling up PCa screening.<sup>[17]</sup> However, the starting age for the screening remains controversial considering the high cost of a nationwide screening. It is hypothesized that the high mortality rate associated with PCa is linked to the age group commonly selected for screening (>70 years). As a good number of affected individuals stand the chance of being missed due to exclusion, the age group of 50–59 years is currently being advocated for screening.<sup>[18,19]</sup> Although the PSA level of > 4 ng/mL is considered appropriate for PCa screening, a PSA level of  $\geq 3$  ng/mL has also been recommended for screening among men  $\leq 60$  years.<sup>[20,21]</sup> It is believed that this will reduce the number of participants that are missed due to age-related low levels of PSA. Despite the fact that PCa is the leading cause of mortality in African men,<sup>[22]</sup> there is little or no concerted effort for a nationwide screening for PCa in West Africa. Most of the screening exercises are academic-related. This has minimal impact on MIR because there is hardly any follow-up on individuals with abnormal PSA, hence the high prevalence of occult PCa in Nigeria (8%).<sup>[23]</sup> Due to the free travel agreement between the Nigeria government and the governments of other West African countries, Nigeria is also inhabited by men from other west African countries. Thus Nigeria, the most populous country in Africa, is largely a microcosm of the West African subregion. The prevalence of abnormal PSA among apparently healthy men in West Africa ranges from 6.6% to 11.2%,<sup>[24-27]</sup> whereas the combined prevalence of abnormal digital rectal examination (DRE) and PSA >4 ng/mL ranges from 5.8% to 7.1%,<sup>[25,26]</sup>

In West Africa, the frequency distribution of BPH and PCa across all age groups appears to be similar due to the fact that the peak incidence of both diseases occurs in the age group of 60–69 years [Figure 2 and Table 1].<sup>[23,28-43]</sup> Although the symptoms of PCa and BPH are also similar, the latter is yet to be established as a direct precursor for the former. However, according to a prospective study carried out by Aghaji and Odoemene,<sup>[44]</sup> 92% of patients (age range = 64–89 years) who were diagnosed with BPH developed PCa one to 10 years postprostatectomy (mean time interval = 6.6 years). According to their follow-up report, approximately 21% of the patients under surveillance died after a period of 1 year. Based on these reports, it is recommended that patients diagnosed of BPH who have had prostatectomy should be actively monitored and tested for germline mutations associated with aggressive PCa, especially those who are >54 years.

### GLEASON SCORE OF PROSTATE CANCER IN WEST AFRICA AND ASIA

GS is a prognostic tool that informs the course of treatment for patients diagnosed with PCa. It identifies cases that are likely to be metastatic.<sup>[7]</sup> Using GS to stratify the death risk among men with PCa, the frequency of low-risk (GS  $\leq 6$ ), intermediate-risk (GS7), and high-risk (GS  $\geq 8$ ) PCa ranges from 42% to 53%, 36% to 41%, and 6% to 15%, respectively, in the USA.<sup>[45-47]</sup> In the UK, the frequency of GS  $\leq 6$ , GS 7, and GS  $\geq 8$  ranges from 38% to 56%, 34% to 38%, and 10% to 21%, respectively,<sup>[48-50]</sup> whereas in Germany the frequency is 11%, 48%, and 36%, respectively.<sup>[51]</sup> These figures suggest that the prevalence of high-risk PCa is lower in the USA, the UK, and Germany than in West Africa and



**Figure 2:** Frequency distribution of benign prostatic hyperplasia across age groups,<sup>[28-33]</sup> showing higher and lower frequency of BPH in the age groups of 60–69 and 30–39 years, respectively, when compared with other groups. It also shows that BPH can be found in individuals younger <40 years of age

Asia [Table 2].<sup>[3,28,29,31,36,37,40,41,52-61]</sup> An earlier study shows that the death risk of patients with a GS of 7 to 10 range from 29% to 43%, irrespective of age.<sup>[62]</sup> This might be due to a lower prevalence of pathogenic mutation (BRCA1/2) in GS ≤ 6 (0.6%) than in GS ≥ 7 (1.2%–3.4%).<sup>[63]</sup> Another study shows that the metastasis hazard ratio of GS8 and

GS9 is 3.5 and 9.3, respectively, when compared with GS7.<sup>[64]</sup>

Currently, the Gleason grading pattern (GG) is being proposed by John Hopkins Hospital as a more reliable tool than the Gleason scoring pattern.<sup>[65]</sup> Of note, the GG pattern

**Table 1: Frequency of prostate cancer across age groups in West Africa**

Year	City	No. of cases	Age range (%)						
			30–39	40–49	50–59	60–69	70–79	80–89	≥ 90
<sup>[34]</sup> 2019	Port H.	676	4 (0.6)	21 (3.1)	122 (18.1)	224 (33.1)	223 (33.0)	73 (10.8)	9 (1.3)
<sup>[35]</sup> 2018	Calabar	563	1 (0.2)	11 (2.0)	104 (18.5)	213 (37.8)	153 (27.2)	59 (10.5)	22 (3.9)
<sup>[36]</sup> 2018	Calabar	111	0 (0.0)	4 (3.6)	20 (18.0)	39 (35.1)	39 (35.1)	6 (5.4)	3 (2.7)
<sup>[37]</sup> 2018	Zaria	211	2 (0.8)	7 (3.3)	38 (18.3)	77 (36.5)	61 (29.0)	23 (10.5)	3 (1.5)
<sup>[23]</sup> 2017*	Lagos	7	0 (0.0)	0 (0.0)	3 (42.9)	1 (14.3)	2 (28.6)	1 (14.3)	0 (0.0)
<sup>[30]</sup> 2017	Enugu	160	7 (4.4)	35 (21.9)	70 (43.8)	34 (21.3)	13 (8.1)	1 (0.6)	0 (0.0)
<sup>[38]</sup> 2015	Ibadan	50	0 (0.0)	1 (2.0)	4 (8.0)	20 (40.0)	25 (50.0)	0 (0.0)	0 (0.0)
<sup>[39]</sup> 2015	Zaria	145	2 (1.3)	7 (4.6)	28 (18.5)	59 (39.0)	49 (32.2)	0 (0.0)	0 (0.0)
<sup>[29]</sup> 2015	Lagos	89	0 (0.0)	2 (2.2)	8 (9.0)	35 (39.3)	35 (39.3)	9 (10.1)	0 (0.0)
<sup>[40]</sup> 2013	Lagos	35	0 (0.0)	1 (2.9)	10 (28.6)	24 (68.6)	0 (0.0)	0 (0.0)	0 (0.0)
<sup>[41]</sup> 2012	Port H.	383	0 (0.0)	4 (1.0)	56 (14.6)	110 (28.7)	154 (40.2)	55 (14.4)	4 (1.0)
<sup>[31]</sup> 2011	Benin	252	0 (0.0)	1 (4.0)	36 (14.3)	88 (34.9)	95 (37.7)	28 (11.1)	4 (1.6)
<sup>[28]</sup> 2011	Lagos	222	0 (0.0)	9 (4.1)	32 (14.4)	95 (42.8)	74 (33.3)	9 (4.1)	3 (1.4)
<sup>[42]</sup> 2010	Ilorin	90	0 (0.0)	4 (4.4)	22 (24.4)	31 (34.4)	24 (26.7)	8 (8.9)	1 (1.1)
<sup>[43]</sup> 2005	Ilorin	114	1 (0.9)	4 (3.5)	16 (14.0)	43 (37.7)	30 (26.3)	7 (6.1)	4 (3.5)
<sup>[33]</sup> 2004	Kano	37	0 (0.0)	2 (5.4)	8 (21.6)	18 (48.6)	6 (16.2)	2 (5.4)	1 (2.7)
<sup>[32]</sup> 2000	Zaria	95	0 (0.0)	4 (4.2)	19 (20.0)	41 (43.2)	29 (30.5)	2 (2.1)	0 (0.0)
<b>Total</b>		<b>3240</b>	<b>17 (0.5)</b>	<b>117 (3.6)</b>	<b>596 (18.4)</b>	<b>1152(35.6)</b>	<b>1012 (31.2)</b>	<b>283 (8.7)</b>	<b>54 (1.7)</b>

H = harcourt

\*Autopsy based (occult PCa)

The table shows higher and lower frequency of PCa in the age groups of 60–69 and 30–39 years, respectively, when compared with other groups. It also shows that PCa can be found in individuals younger <40 years of age

**Table 2: Risk stratification of prostate cancer patients by Gleason score**

Authors/reference	City/country/region	Classification of risk		
		Low	Inter-mediate	High
		GS ≤ 6	GS 7	GS ≥ 8
Obiorah and Ofuru <sup>[34]</sup>	Port H.	282 (41.7)	97 (14.7)	297 (43.9)
Abubakar <i>et al.</i> <sup>[37]</sup>	Zaria	68 (32.2)	43 (20.4)	100 (47.4)
Isiwele <i>et al.</i> <sup>[35]</sup>	Calabar	5 (0.9)	297 (52.8)	261 (46.4)
Bassey <i>et al.</i> <sup>[36]</sup>	Calabar	42 (44.2)	20 (21.1)	33 (33.4)
Nwafor <i>et al.</i> <sup>[29]</sup>	Lagos	21 (33.9)	20 (32.3)	21 (33.9)
Ikuerowo <i>et al.</i> <sup>[40]</sup>	Lagos	11 (25.6)	20 (46.5)	12 (27.9)
Sapira <i>et al.</i> <sup>[41]</sup>	Port H.	58 (30.9)	53 (28.2)	77 (41.0)
Ugare <i>et al.</i> <sup>[52]</sup>	Calabar	33 (37.1)	22 (24.7)	34 (38.2)
Anunobi <i>et al.</i> <sup>[28]</sup>	Lagos	112 (50.9)	20 (9.1)	88 (40.0)
Forae <i>et al.</i> <sup>[31]</sup>	Benin	122 (58.1)	20 (16.4)	68 (32.4)
<b>Total (N = 2357)</b>	<b>West Africa</b>	<b>754 (32.0)</b>	<b>612 (26.0)</b>	<b>991 (42.0)</b>
Uemura <i>et al.</i> <sup>[53]</sup>	UFO	176 (9.1)	465 (24.1)	1288 (66.8)
Farooq <i>et al.</i> <sup>[3]</sup>	India	11 (19.3)	21 (36.8)	25 (43.9)
Awang <i>et al.</i> <sup>[54]</sup>	Malaysia	10 (12.8)	57 (73.1)	11 (14.1)
Heo <i>et al.</i> <sup>[55]</sup>	Korea	218 (32.3)	180 (26.7)	277 (41.0)
Xu <i>et al.</i> <sup>[56]</sup>	China	10 (9.4)	22 (20.8)	69 (65.1)
Zhu <i>et al.</i> <sup>[57]</sup>	China	47 (26.7)	74 (42.0)	55 (31.3)
Sarikaya <i>et al.</i> <sup>[58]</sup>	Turkey	66 (44.6)	35 (23.6)	47 (31.8)
Osman <i>et al.</i> <sup>[59]</sup>	Saudi Arabia	19 (25.0)	24 (31.6)	33 (43.4)
Shahab <i>et al.</i> <sup>[60]</sup>	Indonesia	21 (47.7)	16 (36.4)	7 (15.9)
Tsang <i>et al.</i> <sup>[61]</sup>	Hong Kong	229 (79.8)	42 (14.6)	16 (5.6)
<b>Total (N = 3571)</b>	<b>Asia</b>	<b>807 (22.6)</b>	<b>936 (26.2)</b>	<b>1828 (51.2)</b>

H = harcourt, WA = West Africa, fight against prostate cancer = UFO (countries: n = 8;

Japan, China, South Korea, Singapore, Malaysia, Thailand, Taiwan, India)

The table shows higher prevalence of intermediate-risk and high-risk PCa in Asia than in West Africa (P = 0.211 and P < 0.001, respectively) and shows higher prevalence of low-risk PCa in West Africa than in Asia (P < 0.001)

is yet to be fully and globally used in clinical diagnosis, especially in Africa. In the USA, the prevalence of GG1, GG2, GG3, GG4, and GG5 is approximately 40%, 34%, 13%, 9%, and 4%, respectively.<sup>[46]</sup> Again, these figures show that the prevalence of high-risk PCa is higher in West Africa and Asia [Table 3] than in the USA.<sup>[35-37,39,52,54,58,66-71]</sup> Unlike the GS system which revealed significantly and significantly higher prevalence of intermediate-risk and high-risk PCa in Asia than in West Africa ( $P = 0.211$  and  $P < 0.001$ , respectively), the more reliable GG system revealed significantly higher prevalence of both intermediate-risk (GG3) and high-risk (GG4/5) PCa in West Africa than in Asia ( $P < 0.001$ ). The tool shows that patients with GG1, GG2, GG3, GG4, and GG5 have risk-free survival of 96%, 88%, 63%, 48%, and 26%, respectively.<sup>[72]</sup> The gradual decline in risk-free survival from GG1 to GG5 may be related to the increase in frequency of ataxiatelangiectasia mutated (ATM)/BRCA1/2 mutations from GG1 through GG5; 1.5%, 3.0%, 8.3%, 5.6%, and 6.5%, respectively.<sup>[73]</sup> Wei et al.<sup>[68]</sup> also observed a

higher frequency of GG5 in carriers of germline mutations (BRCA1/2 and ATM) than in noncarriers (65% vs. 46%). They also observed high metastasis in carriers than in noncarriers (71% vs. 58%). As most of the PCa cases in West Africa and Asia are within GG3 to GG5 [Table 3], it is hypothesized that the risk-free survival of patients with PCa is low, especially in West Africa. This is supported by studies that show that 50%–75% of PCa observed in West Africa are either advanced, poorly differentiated or metastatic.<sup>[20-23]</sup>

Furthermore, based on the PSA level, the prevalence of low-, intermediate-, and high-risk PCa in the USA is 23%, 68%, and 10%, respectively.<sup>[74]</sup> This report also shows that the prevalence of high-risk PCa is higher in West Africa and Asia [Table 4] than in the USA.<sup>[33,35-37,58,60,74-76]</sup> In addition, the prevalence of high-risk PCa, based on PSA >10 ng/mL, is higher in West Africa than in Asia ( $P < 0.001$ ). This latter could be considered a tiebreaker between GS and GG patterns of risk stratification and supports the fact that

**Table 3: Risk stratification of prostate cancer patients by Gleason grade**

Authors/reference	City/country/region	Risk stratification				
		Low		Inter-mediate	High	
		GG1	GG2	GG3	GG4	GG5
Emiogun et al. <sup>[66]</sup>	Lagos	37 (12.9)	36 (12.5)	33 (11.5)	58 (20.2)	123 (42.9)
Isiwele et al. <sup>[35]</sup>	Calabar	5 (0.9)	48 (8.5)	249 (44.2)	202 (35.9)	59 (10.5)
Bassey et al. <sup>[36]</sup>	Calabar	12 (11.2)	4 (3.7)	38 (35.5)	34 (31.8)	19 (17.8)
Abubakar et al. <sup>[37]</sup>	Zaria	68 (32.2)	13 (6.2)	29 (13.7)	63 (29.9)	38 (18.0)
Oluwole et al. <sup>[39]</sup>	Zaria	45 (31.0)	10 (6.9)	60 (41.4)	30 (20.7)	0 (0.0)
Ugare et al. <sup>[52]</sup>	Calabar	1 (1.1)	8 (9.0)	22 (24.7)	48 (53.9)	10 (11.2)
<b>Total (N = 1403)</b>	<b>West Africa</b>	<b>168 (12.0)</b>	<b>119 (8.5)</b>	<b>431 (30.7)</b>	<b>435 (31.0)</b>	<b>250 (17.8)</b>
Taguchi et al. <sup>[67]</sup>	Japan	119 (11.6)	395 (38.6)	148 (14.5)	225 (22.0)	135 (13.2)
Wei et al. <sup>[68]</sup>	China	13 (4.2)	25 (8.0)	38 (12.2)	86 (27.5)	150 (48.1)
Awang et al. <sup>[54]</sup>	Malaysia	10 (12.8)	36 (46.2)	21 (26.9)	1 (1.3)	10 (12.8)
Cho et al. <sup>[69]</sup>	South Korea	1349 (46.8)	571 (19.8)	410 (14.2)	406 (14.1)	147 (5.1)
Yeong et al. <sup>[70]</sup>	Singapore	249 (39.0)	258 (40.4)	79 (12.4)	31 (4.9)	21 (3.3)
Khan et al. <sup>[71]</sup>	Pakistan	0 (0.0)	7 (12.3)	8 (14.0)	18 (31.6)	24 (42.1)
Sarikaya et al. <sup>[58]</sup>	Turkey	66 (44.6)	21 (14.2)	14 (9.5)	17 (11.5)	30 (20.3)
<b>Total (N = 5141)</b>	<b>Asia</b>	<b>1809 (35.2)</b>	<b>1313 (25.5)</b>	<b>718 (14.0)</b>	<b>784 (15.2)</b>	<b>517 (10.1)</b>

The table shows higher prevalence of GG4 in both in West Africa and Asia than other GGs. It also reveals higher prevalence of intermediate-risk (GG3) and high-risk (GG4/5) PCa in West Africa than in Asia ( $P < 0.001$ ) but shows lower prevalence of low-risk (GG1/2) PCa in West Africa than in Asia ( $P < 0.001$ )

**Table 4: Risk stratification of patients with prostate cancer by PSA level**

Authors/reference	City/country/region	Classification of risk (PSA level)		
		Low	Inter-mediate	High
		<4 ng/mL	4–10 ng/mL	>10 ng/mL
Abubakar et al. <sup>[37]</sup>	Zaria	0 (0.0)	16 (7.6)	195 (92.4)
Bassey et al. <sup>[36]</sup>	Calabar	7 (6.9)	14 (13.9)	80 (79.2)
Ikuerowo et al. <sup>[35]</sup>	Lagos	0 (0.0)	2 (4.7)	41 (95.3)
Emokpae et al. <sup>[33]</sup>	Kano	3 (8.1)	7 (20.6)	27 (73.0)
<b>Total (N = 392)</b>	<b>West Africa</b>	<b>10 (2.5)</b>	<b>39 (11.9)</b>	<b>343 (87.5)</b>
Wang et al. <sup>[75]</sup>	China	7 (1.6)	173 (40.2)	250 (58.1)
Huang et al. <sup>[76]</sup>	China	9 (6.6)	37 (27.2)	90 (66.2)
Sarikaya et al. <sup>[58]</sup>	Turkey	57 (4.0)	429 (49.3)	24 (52.0)
Shahab et al. <sup>[60]</sup>	Indonesia	17 (4.2)	104 (26.2)	276 (69.6)
Kang et al. <sup>[74]</sup>	Korea	34 (6.8)	233 (46.4)	235 (46.8)
<b>Total (N = 1975)</b>	<b>Asia</b>	<b>124 (6.3)</b>	<b>976 (49.4)</b>	<b>875 (44.3)</b>

The table shows higher prevalence of high-risk PCa in West Africa than in Asia ( $P < 0.001$ ) but lower prevalence of intermediate-risk and low-risk PCa in West Africa than in Asia ( $P < 0.001$  and  $P = 0.004$ , respectively)

the prevalence of high-risk PCa is higher in West Africa than in Asia. The difference between the two regions could be accrued to large-scale PSA screening, early detection germline mutation in high-risk groups, and management of identified cases in Asia.<sup>[77,78]</sup> The high frequency of PCa in the age group of 50–59 years [Table 1] further compounds the issue of high MIR in West Africa.<sup>[79,80]</sup> This calls for a review of the starting age for PSA testing. Although Carlsson *et al.*<sup>[19]</sup> advocate that screening should start at  $\geq 50$  years, it will be more appropriate for screening to start at  $\geq 40$  years in West Africa, as earlier proposed by Vickers *et al.*,<sup>[81]</sup> considering that 18.9% of PCa in the region occurs in the age range of 50–59 years. Thus, starting the screening exercise at  $\geq 40$  years may forestall the progression of the disease and reduce the mortality rate of PCa in the age range of 50–69 years.

## RACE AND ANCESTRAL MIGRATION INFLUENCES ON INCIDENCE AND MORTALITY

Ancestral migration has been shown to increase the incidence of PCa among Asians and Africans.<sup>[16]</sup> In England, the age-standardized incidence rate (ASR) of PCa per 100,000 for Black African and Black Caribbean is 99.2 and 110.1, respectively, whereas that of white and Asian is 44.9 and 21.3, respectively.<sup>[82]</sup> Interestingly, country-of-origin based GLOBACON estimate shows that ASR incidence of PCa for Black African and Black Caribbean is 21.1 and 71.1, respectively, whereas that of Asians ranges from 1.9 to 5.1.<sup>[82]</sup> Possibly, emigrational amplification of mutated genes may be occurring considering the fact that the incidence of PCa in men living in West Africa (61.3–127) is lower than the incidence in men with African ancestry who are living in the Caribbean (56.4–304), United State (258.3) and Europe (139.3–647.0).<sup>[83]</sup> As at 2004, the incidence–mortality ratio of PCa in Chinese men and Chinese-Americans is approximately 1:50 and 1:9, respectively.<sup>[84]</sup> This further supports the fact that race and ancestral migration favors higher incidence rates of PCa in offspring. According to literature review carried out by Chung *et al.*<sup>[11]</sup> in Asia countries, age, family history, consumption of fat, eggs, red meat, fat, and dairy are risk factors for PCa.

Higher mortality rate has also been reported in Black Non-Hispanics PCa patients (47.2%) than in white Hispanic PCa (19.9%).<sup>[14]</sup> According to Heyns's review, the mortality ratio between blacks and whites diagnosed of PCa is 2.4:1.<sup>[85]</sup> The race related differences in mortality of patients with PCa could be linked to variation of mutation frequency. This is buttressed by the fact that the prevalence of BRCA1 and BRCA2 are higher in blacks than in whites (14.3% vs. 5.0% and 3.6% vs. 3.5%, respectively), whereas the

prevalence of ATM is higher in white than in blacks (0.7% vs. 0.0%).<sup>[86]</sup> A recently published study reveals that the standard mortality rate (SMR) of BRCA1 and BRCA2 were 1.8 and 3.9, respectively.<sup>[50]</sup> These reports suggest that ancestral or family history and environmental factors determine the degree to which an individual is affected by germline mutations.

## RELATIONSHIP BETWEEN RACE, FAMILY HISTORY, AND AGGRESSIVE PROSTATE CANCER

PCa is the most inherited cancer.<sup>[27]</sup> According to Pritchard,<sup>[87]</sup> the prevalence of pathogenic germline mutation is higher in PCa patients who have a first degree relative with breast, ovarian or colorectal cancer (71%) than in those without an affected first degree relative (22%). The effect of family history is commonly seen in blacks than in Whites.<sup>[88]</sup> In the USA, the prevalence of pathogenic mutation in BRCA1/2 is higher in African American (1.4%) than in Caucasians (1.0%).<sup>[63]</sup> The reason for the difference could be due to some inherited genes or family history. This is underscored by the reports of Chandrasekar *et al.*<sup>[86]</sup> which shows that the prevalence of hereditary PCa (HPC) are higher in blacks than in white, with differences of 1.2%. According to Lindström *et al.*,<sup>[89]</sup> family history is strongly associated with lethal/aggressive PCa. Their study revealed that a poor father survival implies a poor son survival with hazard ratio of 2.07. Approximately 12% of DNA repair genes occur in men with metastatic PCa than in the general population.<sup>[88]</sup> Following genome-wide investigations, approximately 163 single-nucleotide polymorphisms (SNPs) have been linked to the development of PCa. These SNP accounts for 28% of the family history associated with PCa. Individually, these SNPs exact minor effects but collectively they prove debilitating. Individuals with the SNPs are considered to have low and high genetic risk score (GRS) than the general population when their risk odd ratios are less than 1 and greater than 1, respectively.<sup>[90]</sup> In other to identify men who should be actively monitored for PCa, GRS appears to be a broad and reliable risk index for PCa than DNA repair genes (BRCA2 and ATM) or family history.<sup>[90]</sup> However, BRCA1/2 mutations are early indicators of PCa, whereas ATM mutation identifies individuals at risk of developing aggressive or metastatic PCa.<sup>[50,88]</sup> Thus, testing for a combination of GRS, BRCA1/2 and ATM with active follow up of positive individuals may reduce PCa related mortality to a great extent.

## CONCLUSION

The high prevalence of high-risk PCa in Asia and West Africa, when compared with the USA, the UK, and Germany,

could be a reflection of the level of screening and treatment of identified cases in both regions. The lower prevalence of high-risk PCa in Asia when compared with West Africa could be due to race, differences in family history and inherited germline mutations. However, it is unclear whether the low interest in identifying germline mutations in West African patients is due to low incidence of the disease in the subcontinent or lack of funds. Screening individuals who are aged >50 and ≤ 69 years and with a family history of prostate, breast, ovarian or pancreatic cancer, or Lynch syndrome may improve stratification and eliminate the need to test the entire patients, thereby lowering the cost of testing for germline mutations. Testing for BRCA2, BRCA1 and ATM in selected patients who have GS ≥ 7 or GG ≥ 3, high prostate density, low prostate volume and PSA levels of >4.0 ng/mL may aid early identification of men at risk of developing lethal or aggressive PCa.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Lakhtakia R, Bharadwaj R, Kumar VK, Mandal P, Nema SK. Immunophenotypic characterization of benign and malignant prostatic lesions. *Med J Armed Forces India* 2007;63:243-8.
- Garg M, Kaur G, Malhotra V, Garg R. Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions. *Prostate Int* 2013;1:146-51.
- Farooq S, Bilal S, Khaliq BI, Sidiq F, Aslam H, Shah I. The spectrum of histopathological patterns observed in prostate specimens in a tertiary care hospital in Kashmir. *Int J Contemp Med Res* 2019;6:D1-3.
- Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, *et al.* Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. *JAMA Oncol* 2018;4:1553-68.
- Small E. Cecil Textbook of Medicine, Prostate Cancer. Philadelphia: WB Saunders; 2004.
- Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, *et al.* Prostate cancer, version 3.2012: Featured updates to the NCCN guidelines. *J Natl Compr Canc Netw* 2012;10:1081-7.
- Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. *Am J Surg Pathol* 2005;29:1228-42.
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
- Chen SL, Wang SC, Ho CJ, Kao YL, Hsieh TY, Chen WJ, *et al.* Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. *Sci Rep* 2017;7:40003.
- Donnelly DW, Gavin A, Downing A, Hounsborne L, Kearney T, McNair E, *et al.* Regional variations in quality of survival among men with prostate cancer across the United Kingdom. *Eur Urol* 2019;76:228-37.
- Chung BH, Horie S, Chiong E. Clinical studies investigating the use of leuporelin for prostate cancer in Asia. *Prostate Int* 2020;8:1-9.
- Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. *Eur Urol* 2020;77:38-52.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
- Taitt HE. Global trends and prostate cancer: A review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. *Am J Mens Health* 2018;12:1807-23.
- Chen R, Ren S, Yiu MK, Fai NC, Cheng WS, Ian LH, *et al.*; Chinese Prostate Cancer Consortium. Prostate cancer in Asia: A collaborative report. *Asian J Urol* 2014;1:15-29.
- Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. *Prostate Int* 2013;1:47-58.
- Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, *et al.* Prostate-specific antigen (PSA) and PSA density: Racial differences in men without prostate cancer. *J Natl Cancer Inst* 1997;89:134-8.
- Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, *et al.* Mortality results from the göteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol* 2010;11:725-32.
- Carlsson S, Assel M, Ulmert D, Gerdtsen A, Hugosson J, Vickers A, *et al.* Screening for prostate cancer starting at age 50-54 years. A population-based cohort study. *Eur Urol* 2017;71:46-52.
- Pashayan N, Pharoah P, Neal DE, Hamdy F, Donovan J, Martin RM, *et al.* Stage shift in PSA-detected prostate cancers—effect modification by Gleason score. *J Med Screen* 2009;16:98-101.
- Garg V, Gu NY, Borrego ME, Raisch DW. A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening. *Expert Rev Pharmacoecon Outcomes Res* 2013;13:327-42.
- Awodele O, Adeyomoye AA, Awodele DF, Fayankinu VB, Dolapo DC. Cancer distribution pattern in south-western Nigeria. *Tanzan J Health Res* 2011;13:125-31.
- Imasogie DE, Azeke AT. Prostatic adenocarcinoma and prostatic intraepithelial neoplasia: A tale of the autopsy model in a Nigerian tertiary hospital. *Niger J Surg Sci* 2017;27:41-6.
- Erhabor O, Zama I, Mainasara AS, Shehu RA, Iwueke IP, Festus A, *et al.* Prostate Specific Antigen (PSA) screening among apparently healthy men of African descent in Sokoto, North Western, Nigeria. *Int Blood Res Rev* 2014;2:37-47.
- Akinremi T, Adeniyi A, Olutunde A, Oduniyi A, Ogo C. Need for and relevance of prostate cancer screening in Nigeria. *Ecancermedalscience* 2014;8:457.
- Ukoli F, Osime U, Akereyeni F, Okunzuwa O, Kittles R, Adams-Campbell L. Prevalence of elevated serum prostate-specific antigen in rural Nigeria. *Int J Urol* 2003;10:315-22.
- Ikuerowo SO, Ajala MO, Abolarinwa AA, Omisano OA. Age-specific serum prostate specific antigen ranges among apparently healthy Nigerian men without clinical evidence of prostate cancer. *Niger J Surg* 2016;22:5-8.
- Anunobi CC, Akinde OR, Elesha SO, Daramola AO, Tijani KH, Ojewola RW. Prostate diseases in Lagos, Nigeria: A histologic study with TPSA correlation. *Niger Postgrad Med J* 2011;18:98-104.
- Nwafor CC, Keshinro OS, Abudu EK. A histological study of prostate lesions in Lagos, Nigeria: A private practice experience. *Nig Med J* 2015;56:338-43.
- Ugwumba FO, Ozoemena OF, Okoh AD, Echeta KN, Mbadiwe OM. Transvesical prostatectomy in the management of benign prostatic hyperplasia in a developing country. *Niger J Clin Pract* 2014;17:797-801.
- Forae G, Obaseki DE, Aligbe JU, Ekanem VJ. Morphological patterns of prostatic lesions in Benin city, Nigeria: A twenty year retrospective study. *Ann Trop Pathol* 2011;2:23-8.
- Dawam D, Rafindadi AH, Kalayi GD. Benign prostatic hyperplasia and prostate carcinoma in native Africans. *BJU Int* 2000;85:1074-7.

33. Emokpae MA, Das SC, Orok T, Mohammed AZ, Hassan SA. Early detection of prostate cancer: Evaluating the diagnostic performance of prostate specific antigen by comparing with histological technique among Africans. *Indian J Clin Biochem* 2004;19:62-6.
34. Obiorah CC, Ofuru V. A Population based study of prostate cancer in rivers state, Nigeria. *Int J Biomed Sci* 2019;15:57-62.
35. Isiwele EM, Bassey IAE, Ikpi EE, Enakirerhi GE, Ootobo FO, Essiet A, *et al.* Histopathologic patterns of urological malignancies in Calabar, South-Southern Nigeria: A ten-year review. *J Cancer Tumor Int* 2018;8:1-10.
36. Bassey IA, Isiwele EM, Debua A. Prognostication studies of prostate cancer in black Africa: Findings from Calabar, South-South, Nigeria. *Int J Cont Med Res* 2018;5:E1-5.
37. Abubakar M, Shehu SM, Ahmed SA, Liman AA, Akpobi KC, Mohammed A, *et al.* Adenocarcinoma of the prostate: Correlation between serum prostate-specific-antigen and Gleason grade group. *Ann Trop Pathol* 2018;9:126-30.
38. Agalliu I, Adebisi AO, Lounsbury DW, Popoola O, Jinadu K, Amodu O, *et al.* The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria. *BMC Public Health* 2015;15:425.
39. Oluwale OP, Rafindadi AH, Shehu MS, Samaila MOA. A ten-year study of prostate cancer specimens at Ahmadu Bello University Teaching Hospital (A.B.U.T.H.), Zaria, Nigeria. *Afr J Urol* 2015;21:15-8.
40. Ikwerowo SO, Omisanjo OA, Bioku MJ, Ajala MO, Mordi VP, Esho JO. Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. *Pan Afr Med J* 2013;15:129.
41. Sapira MK, Obiorah CC. Age and pathology of prostate cancer in south-southern Nigeria; is there a pattern? *Med J Malaysia* 2012;67:417-9.
42. Ajape AA, Ibrahim KO, Fakeye JA, Abiola OO. An overview of cancer of the prostate diagnosis and management in Nigeria: The experience in a Nigerian tertiary hospital. *Ann Afr Med* 2010;9:113-7.
43. Mohammed AZ, Nwana EJC, Anjorin AS. Histopathological pattern of prostatic diseases in Nigerians. *Afr J Urol* 2005;11:33-8.
44. Aghaji AE, Odoemene CA. Prostatic cancer after prostatectomy for benign prostatic hyperplasia in Nigeria. *East Afr Med J* 2000;77:635-9.
45. Herget KA, Patel DP, Hanson HA, Sweeney C, Lowrance WT. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. *Cancer Med* 2016;5:136-41.
46. Buie J, De Riese W, Sharma P. Smaller prostate volume is associated with adverse pathological features and biochemical recurrence after radical prostatectomy. *Urol Sci* 2019;30:255-61.
47. Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, *et al.* Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. *BMC Cancer* 2015;15:259.
48. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, *et al.*; IMPACT Study Collaborators. Interim results from the IMPACT study: Evidence for prostate-specific antigen screening in BRCA2 mutation carriers. *Eur Urol* 2019;76:831-42.
49. Leongamornlert DA, Saunders EJ, Wakerell S, Whitmore I, Dadaev T, Cieza-Borrella C, *et al.* Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: Evidence for a more extensive genetic panel. *Eur Urol* 2019;76:329-37.
50. Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, *et al.* Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: A prospective cohort study. *Eur Urol* 2020;77:24-35.
51. Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, *et al.* Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. *Eur Urol* 2019;76:517-23.
52. Ugare UG, Bassey IE, Jibrin PG, Ekanem IA. Analysis of Gleason grade and scores in 90 Nigerian Africans with prostate cancer during the period 1994 to 2004. *Afr Health Sci* 2012;12:69-73.
53. Uemura H, Ye D, Kanesvaran R, Chiong E, Lojanapiwat B, Pu YS, *et al.* United in fight against prostate cancer (UFO) registry: First results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. *BJU Int* 2020;125:541-52.
54. Awang A, Md Isa N, Yunus R, Azhar Shah S, Md Pauzi SH. Gleason scores in prostate needle biopsy and prostatectomy specimens in prostatic adenocarcinoma: A correlation study. *Malays J Pathol* 2019;41:253-7.
55. Heo JE, Ahn HK, Kim J, Chung BH, Lee KS. Changes in clinical characteristics of patients with an initial diagnosis of prostate cancer in Korea: 10-year trends reported by a tertiary center. *J Korean Med Sci* 2018;33:e42.
56. Xu Y, Yang X, Si T, Yu H, Zhang W, Li Y, *et al.* Clinicopathological and prognostic factors in 106 prostate cancer patients aged ≤55 years: A single-center study in china. *Med Sci Monit* 2016;22:3935-42.
57. Zhu Y, Han CT, Chen HT, Liu F, Zhang GM, Yang WY, *et al.* Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort. *Oncotarget* 2015;6:22978-84.
58. Sarikaya S, Resorlu M, Oguz U, Yordam M, Bozkurt OF, Unsal A. Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: Our experience and review of the literature. *Arch Ital Urol Androl* 2014;86:288-90.
59. Osman E, Gomha MA, Harb A, Aldayel A, Aloraifi I, Almousa R, *et al.* An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the eastern province. *Arab J Urol* 2014;12:187-91.
60. Shahab AA, Soebadi DM, Djatisoesanto W, Hardjowijoto S, Soetojo S, Hakim L. Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer. *Prostate Int* 2013;1:23-30.
61. Tsang CF, Tsu JH, Lai TC, Wong KW, Ho BS, Ng AT, *et al.* Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: Comparison of six different active surveillance protocols. *Hong Kong Med J* 2017;23:609-15.
62. Graham J, Baker M, Macbeth F, Titshall V; Guideline Development Group. Diagnosis and treatment of prostate cancer: Summary of NICE guidance. *BMJ* 2008;336:610-2.
63. Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, *et al.* Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. *Prostate Cancer Prostatic Dis* 2019;22:406-10.
64. Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, *et al.* Clinical validation of the 2005 ISUP Gleason grading system in a cohort of intermediate and high risk men undergoing radical prostatectomy. *PLOS ONE* 2016;11:e0146189.
65. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: Data based on the modified Gleason scoring system. *BJU Int* 2013;111:753-60.
66. Emiogun FE, Williams OO, Obafunwa JO. Epidemiology of prostate cancer in Nigeria: Observations at Lagos State University Teaching Hospital. *Cancer Health Disparities* 2019. [Ahead of Print]
67. Taguchi S, Uemura Y, Fujimura T, Morikawa T, Naito A, Kawai T, *et al.* Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: Development of the modified Gleason grade grouping (mGGG) model. *BMC Cancer* 2020;20:371.
68. Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, *et al.* Germline DNA repair gene mutation landscape in Chinese prostate cancer patients. *Eur Urol* 2019;76:280-3.
69. Cho M, Yoo S, Park J, Jeong CW, Ku JH, Kwak C, *et al.* Value of the new 5-tiered prostate cancer grade group system on predicting oncological outcomes for radical prostatectomy population in Korea. *Korean J Urol Oncol* 2018;16:75-81.
70. Yeong J, Sultana R, Teo J, Huang HH, Yuen J, Tan PH, *et al.* Gleason grade grouping of prostate cancer is of prognostic value in Asian men. *J Clin Pathol* 2017;70:745-53.



71. Khan MA, Shah H, Gul M. Prognostic stratification of prostatic cancer according to modified Gleason grading system. *J Rawalpindi Med College* 2016;20:281-4.
72. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, *et al.* A contemporary prostate cancer grading system: A validated alternative to the Gleason score. *Eur Urol* 2016;69:428-35.
73. Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: Association of Gleason score and tumor stage. *Prostate Cancer Prostatic Dis* 2019;22:59-65.
74. Kang DI, Chung JI, Ha HK, Min K, Yoon J, Kim W, *et al.* Korean prostate cancer patients have worse disease characteristics than their American counterparts. *Asian Pac J Cancer Prev* 2013;14:6913-7.
75. Wang FB, Chen R, Ren SC, Shi XL, Zhu YS, Zhang W, *et al.* Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy. *Asian J Androl* 2017;19:238-43.
76. Huang J, Reilly KH, Zhang HZ, Wang HB. Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia. *BMC Urol* 2015;15:118.
77. Kitagawa Y, Namiki M. Prostate-specific antigen-based population screening for prostate cancer: Current status in Japan and future perspective in Asia. *Asian J Androl* 2015;17:475-80.
78. Lee HY, Park S, Doo SW, Yang WJ, Song YS, Kim JH. Trends in prostate cancer prevalence and radical prostatectomy rate according to age structural changes in South Korea between 2005 and 2015. *Yonsei Med J* 2019;60:257-66.
79. Ifere GO, Abebe F, Ananaba GA. Emergent trends in the reported incidence of prostate cancer in Nigeria. *Clin Epidemiol* 2012;4:19-32.
80. Hsing AW, Yeboah E, Biritwum R, Tettey Y, De Marzo AM, Adjei A, *et al.* High prevalence of screen detected prostate cancer in West Africans: Implications for racial disparity of prostate cancer. *J Urol* 2014;192:730-5.
81. Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsen A, *et al.* Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: Case-control study. *BMJ* 2013;346:f2023.
82. Maruthappu M, Barnes I, Sayeed S, Ali R. Incidence of prostate and urological cancers in England by ethnic group, 2001-2007: A descriptive study. *BMC Cancer* 2015;15:753.
83. Odedina FT, Akinremi TO, Chingwundoh F, Roberts R, Yu D, Reams RR, *et al.* Prostate cancer disparities in Black men of African descent: A comparative literature review of prostate cancer burden among black men in the United States, Caribbean, United Kingdom, and West Africa. *Infect Agents Cancer* 2009;4:52.
84. Zhang L, Wu S, Guo LR, Zhao XJ. Diagnostic strategies and the incidence of prostate cancer: Reasons for the low reported incidence of prostate cancer in china. *Asian J Androl* 2009;11:9-13.
85. Heyns CF. Is prostate cancer more common and more aggressive in African men? *Afr J Urol* 2008;14:66-74.
86. Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN. Prevalence of suspected hereditary cancer syndromes and germline mutations among a diverse cohort of probands reporting a family history of prostate cancer: Toward informing cascade testing for men. *Eur Urol Oncol* 2020;3:291-7.
87. Pritchard CC. Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness. *Can J Urol* 2019;26:24-6.
88. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, *et al.* Inherited DNA-repair gene mutations in men with metastatic prostate cancer. *N Engl J Med* 2016;375:443-53.
89. Lindström LS, Hall P, Hartman M, Wiklund F, Grönberg H, Czene K. Familial concordance in cancer survival: A Swedish population-based study. *Lancet Oncol* 2007;8:1001-6.
90. Isaacs WB, Xu J. Current progress and questions in germline genetics of prostate cancer. *Asian J Urol* 2019;6:3-9.